Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study
- PMID:16234520
- DOI: 10.1200/JCO.2005.05.525
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study
Abstract
Purpose: Prostate growth and differentiation are under androgenic control, and prior studies suggested that tumors that develop in hypogonadal men are more aggressive. We examined whether prostate weight was associated with tumor grade, advanced disease, or risk of biochemical progression after radical prostatectomy (RP).
Patients and methods: We evaluated the association of prostate weight with pathologic tumor grade, positive surgical margins, extracapsular disease, and seminal vesicle invasion using logistic regression and with biochemical progression using Cox proportional hazards regression among 1,602 men treated with RP between 1988 and 2003 at five equal-access medical centers, which composed the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.
Results: In outcome prediction models including multiple predictor variables, it was found that the predictor variable of prostate weight was significantly inversely associated with the outcomes of high-grade disease, positive surgical margins, extracapsular extension (all P < or = .004), and biochemical progression (comparing prostate weight < 20 v > or = 100 g: relative risk = 8.43; 95% CI, 2.9 to 24.0; P < .001). Similar associations were seen between preoperative transrectal ultrasound-measured prostate volume and high-grade disease, positive surgical margins, extracapsular extension (all P < or = .005), seminal vesicle invasion (P = .07), and biochemical progression (P = .06).
Conclusion: Men with smaller prostates had more high-grade cancers and more advanced disease and were at greater risk of progression after RP. These results suggest that prostate size may be an important prognostic variable that should be evaluated for use pre- and postoperatively to predict biochemical progression.
Comment in
- Words of wisdom. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study.Zlotta AR.Zlotta AR.Eur Urol. 2006 Apr;49(4):757-8. doi: 10.1016/j.eururo.2006.02.006.Eur Urol. 2006.PMID:17605165No abstract available.
Similar articles
- Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.Freedland SJ, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Dorey F, Aronson WJ.Freedland SJ, et al.J Urol. 2003 Mar;169(3):969-73. doi: 10.1097/01.ju.0000051400.85694.bb.J Urol. 2003.PMID:12576824
- PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.Freedland SJ, Hotaling JM, Fitzsimons NJ, Presti JC Jr, Kane CJ, Terris MK, Aronson WJ, Amling CL.Freedland SJ, et al.Eur Urol. 2008 Apr;53(4):758-64; discussion 765-6. doi: 10.1016/j.eururo.2007.08.047. Epub 2007 Aug 31.Eur Urol. 2008.PMID:17868976
- Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy.Freedland SJ, Aronson WJ, Presti JC Jr, Amling CL, Terris MK, Trock B, Kane CJ.Freedland SJ, et al.Cancer. 2004 Apr 15;100(8):1633-8. doi: 10.1002/cncr.20122.Cancer. 2004.PMID:15073850
- Meta-analysis of metabolic syndrome and prostate cancer.Gacci M, Russo GI, De Nunzio C, Sebastianelli A, Salvi M, Vignozzi L, Tubaro A, Morgia G, Serni S.Gacci M, et al.Prostate Cancer Prostatic Dis. 2017 Jun;20(2):146-155. doi: 10.1038/pcan.2017.1. Epub 2017 Feb 21.Prostate Cancer Prostatic Dis. 2017.PMID:28220805Review.
- [Pathological interpretation of radical prostatectomy].Molinié V.Molinié V.Ann Urol (Paris). 2006 Dec;40 Suppl 2:S32-4. doi: 10.1016/s0003-4401(06)80017-3.Ann Urol (Paris). 2006.PMID:17361917Review.French.
Cited by
- Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis.de Boo L, Pintilie M, Yip P, Baniel J, Fleshner N, Margel D.de Boo L, et al.Can Urol Assoc J. 2015 Jan-Feb;9(1-2):E14-21. doi: 10.5489/cuaj.2147.Can Urol Assoc J. 2015.PMID:25624961Free PMC article.
- Is Additional Systematic Biopsy Necessary in All Initial Prostate Biopsy Patients With Abnormal MRI?Cheng X, Xu J, Chen Y, Liu Z, Sun G, Yang L, Yao J, Zeng H, Song B.Cheng X, et al.Front Oncol. 2021 Feb 26;11:643051. doi: 10.3389/fonc.2021.643051. eCollection 2021.Front Oncol. 2021.PMID:33718240Free PMC article.
- Perioperative, function, and positive surgical margin in extraperitoneal versus transperitoneal single port robot-assisted radical prostatectomy: a systematic review and meta-analysis.Jiang Y, Liu Y, Qin S, Zhong S, Huang X.Jiang Y, et al.World J Surg Oncol. 2023 Dec 12;21(1):383. doi: 10.1186/s12957-023-03272-7.World J Surg Oncol. 2023.PMID:38087327Free PMC article.Review.
- Obesity and cancer.Wolin KY, Carson K, Colditz GA.Wolin KY, et al.Oncologist. 2010;15(6):556-65. doi: 10.1634/theoncologist.2009-0285. Epub 2010 May 27.Oncologist. 2010.PMID:20507889Free PMC article.Review.
- Risk stratification in the hormonal treatment of patients with prostate cancer.Uhlman MA, Moul JW, Tang P, Stackhouse DA, Sun L.Uhlman MA, et al.Ther Adv Med Oncol. 2009 Sep;1(2):79-94. doi: 10.1177/1758834009340164.Ther Adv Med Oncol. 2009.PMID:21789114Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical